Company No: 04210685 (England and Wales)

Contents

• Company Information
• Balance Sheet
• Notes to the Financial Statements

DIRECTORS	Alfred David Allen
	Richard Oliver Allen

REGISTERED OFFICE	Treviot House
	186-192 High Road
	Ilford
	IG1 1LR
	United Kingdom

COMPANY NUMBER

04210685 (England and Wales)

ACCOUNTANT	Gravita Essex Limited
	Kings House
	101-135 Kings Road
	Brentwood
	Essex
	CM14 4DR
	United Kingdom

	Note	2026		2025
		£		£
Fixed assets
Tangible assets	3	3,672		5,954
Investments	4	100		100
		3,772		6,054
Current assets
Stocks	5	139,716		70,302
Debtors	6	280,325		281,613
Cash at bank and in hand	7	1,289,121		1,992,556
		1,709,162		2,344,471
Creditors: amounts falling due within one year	8	( 384,661)		( 1,017,054)
Net current assets		1,324,501		1,327,417
Total assets less current liabilities		1,328,273		1,333,471
Net assets		1,328,273		1,333,471
Capital and reserves
Called-up share capital		201		201
Profit and loss account		1,328,072		1,333,270
Total shareholders' funds		1,328,273		1,333,471

For the financial year ending 30 June 2026 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
• The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
• These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Income Statement has not been delivered.

The financial statements of ADAllen Pharma Limited (registered number: 04210685) were approved and authorised for issue by the Board of Directors on 08 October 2026. They were signed on its behalf by:

Richard Oliver Allen Director

1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

ADAllen Pharma Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Treviot House, 186-192 High Road, Ilford, IG1 1LR, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Foreign currency

Transactions in foreign currencies are recorded at the rate of exchange at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the Balance Sheet date are reported at the rates of exchange prevailing at that date.

Exchange differences are recognised in the Income Statement in the period in which they arise except for exchange differences arising on gains or losses on non-monetary items which are recognised in the Statement of Comprehensive Income.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Balance Sheet date.

Intangible assets

Intangible assets are stated at cost or valuation, net of amortisation and any provision for impairment. Amortisation is provided on all intangible assets at rates to write off the cost or valuation of each asset over its expected useful life as follows:

Goodwill

10 years straight line

Goodwill

Goodwill arises on business combination and represents any excess of consideration given over the fair value of the identifiable assets and liabilities acquired. Goodwill is initially recognised as an intangible asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is amortised on a straight line basis over its useful economic life, which is 10 years.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery	25 % reducing balance
Fixtures and fittings	25 % reducing balance
Computer equipment	33 % reducing balance

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

2. Employees

	2026		2025
	Number		Number
Monthly average number of persons employed by the Company during the year, including directors	11		13

3. Tangible assets

	Plant and machinery		Fixtures and fittings		Computer equipment		Total
	£		£		£		£
Cost
At 01 July 2025	73,500		81,274		75,941		230,715
Additions	0		0		667		667
At 30 June 2026	73,500		81,274		76,608		231,382
Accumulated depreciation
At 01 July 2025	73,500		79,116		72,145		224,761
Charge for the financial year	0		470		2,479		2,949
At 30 June 2026	73,500		79,586		74,624		227,710
Net book value
At 30 June 2026	0		1,688		1,984		3,672
At 30 June 2025	0		2,158		3,796		5,954

4. Fixed asset investments

Investments in subsidiaries

	2026
	£
Cost
At 01 July 2025	100
At 30 June 2026	100
Carrying value at 30 June 2026	100
Carrying value at 30 June 2025	100

5. Stocks

	2026		2025
	£		£
Stocks	139,716		70,302

6. Debtors

	2026		2025
	£		£
Trade debtors	170,973		196,932
Amounts owed by Group undertakings	92,797		72,311
Other debtors	16,555		12,370
	280,325		281,613

7. Cash and cash equivalents

	2026		2025
	£		£
Cash at bank and in hand	1,289,121		1,992,556

8. Creditors: amounts falling due within one year

	2026		2025
	£		£
Trade creditors	250,838		610,956
Taxation and social security	26,484		82,719
Other creditors	107,339		323,379
	384,661		1,017,054